COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

September 06, 2017 - October 27, 2017

COMMITTEE DURATION: 8 WEEKSk

alea	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	IDCM	22		2 (4 Groups)		**24**
	PHARMACOLOGY	PC	24				**24**
	PATHOLOGY	PT	18				**18**
	PUBLIC HEALTH	PH	8				**8**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	10				**10**
	HEMATOLOGY	HEM	17				**17**
	BIOSTATISTICS	BS	8				**8**
	INTERNAL MEDICINE	IM	2				**2**
	PATHOPHYSIOLOGY	PP	4				**4**
	FAMILY MEDICINE	FM	3				**3**
	MEDICAL GENETICS	MG	5				**5**
	EMERGENCY MEDICINE	EM	1				**1**
	PEDIATRICS	PED	8				**8**
	PHYTOTHERAPY	PHY	3				**3**
	ONCOLOGY	ONC	3				**3**
	RADIATION ONCOLOGY	RONC	2				**2**
	SCIENTIFIC PROJECTS-III	SP	2				**2**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2 X 3=6 (4 Groups)		**6**
TOTAL			**72**		**5**	**2**	**79**

Coordination Committee

HEAD	Meral Sönmezoğlu, MD, Prof.
SECRETARY	Orhan Önder Eren, MD, Asst. Prof
MEMBER	Yaşar Küçükardalı, MD, Prof.
MEMBER	Ayşegül Kuşkucu, MD, Asst. Prof.
MEMBER	Atilla Özkan , MD, Assoc. Prof

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES AND MEDICAL MICROBIOLOGY	Meral Sönmezoğlu, MD, Prof. İ. Çağatay Acuner, MD, Assoc. Prof. Barış Ata Borsa, Asst. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof. Ahmet Sedat Çöloğlu, DMD, Prof.
HEMATOLOGY	Atilla Özkan, MD, Assoc.Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof Hülya Sarıçoban, MD, Assoc. Prof. Sema Yılmaz, MD, Assoc. Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Asst. Prof
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, Assoc. Prof.
PEDIATRICS	Filiz Bakar MD, Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof. Hülya Akan, MD, Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD. Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Asst Prof.
BIOISTATISTICS	Çiğdem Altunok, PhD, Asst. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, Asst. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
ONCOLOGY	Orhan Önder Eren, MD, Asst. Prof.
RADIATION ONCOLOGY	Halim Aydın, MD, Assoc. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Asst. Prof. Pınar Tura, MD, Asst. Prof.

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

INFECTIOUS DISEASES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2.1. ***recall*** structures, and
2.2. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3.0. ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,

4.0. ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0. ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0. ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0. ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0. ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination

9.2. evaluation of emergency case (sepsis and septic shock-C1)

9.3. approach to healthy individual or patient (fever-C1)

9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)

9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)

9.6. point of care testing (urine strip/dipstick test-C1)

9.7. making preliminary diagnosis or definitive diagnosis decision

9.8. making non-intervention or intervention decision

9.9. practicing non-intervention or intervention

9.10. referral/transport of healthy individual or patient

10.1.***list*** goals and principles of drug use,

10.2.***describe*** effects,

10.3.***explain*** mechanism of action (pharmacodynamics),

10.4.***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,

10.5.***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0. ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0.***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

14.0. ***explain*** hereditary immune system disorders,

15.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

16.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
17.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.
18.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,
19.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,
20.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

HEMATOPOIETIC SYSTEM

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,
11. ***to equip with*** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of hematopoietic system,
2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,

4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,
   - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
   - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
   - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination
6.2. evaluation of emergency case
6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***classify*** blood products and blood groups,
8. ***define*** principles of transfusion,
9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. ***list*** principles of cancer chemotherapy,
12. ***explain*** chemotherapy in leukemia and lymphoma,
13. ***list*** phytotherapeutic agents with immunomodulatory effects,
14. ***list*** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.
16. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM
COMMITTEE ASSESSMENT MATRIX

PHASE III - COURSE: MD 320 INTRODUCTION TO CLINICAL SCIENCES **COURSE COMPONENT:** COMMITTEE I - INFECTIOUS DISEASES & HEMATOPOIETIC SYSTEM						
QUESTION DISTRIBUTION TABLE						
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/ INSTRUCTOR**	**NUMBER OF QUESTIONS (MCQ)**			
			CE	**FE**	**IE**	**Total**
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu	16	6	6	**28**
1.0.,3.0. (4.0.-12.0.)		İ.Ç.Acuner				
		B.A. Borsa				
	HEM	H.A. Özkan	9	3	3	**15**
	ONC	O.Ö.Eren	2	1	1	**4**
	RONC	H.Aydın	1	0	0	**1**
10.0.	PC	E.Genç	17	9	9	**35**
4.0.,5.0.	PT	F. Özkan	10	5	5	**20**
4.0.,5.0.		I. D. Ekici				
4.0., 5.0.		A.S.Çöloğlu				
6.0.,7.0.,11.0.,12.0.	PH	R.E. Sezer	5	2	2	**14**
6.0.,7.0.,11.0.,12.0.		H.A.Taşyıkan				
15.0.	BED		6	2	2	**14**
16.0.	BS	Ç. Altunok	8	2	2	**12**
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	Ö. Tanrıöver	4	1	1	**5**
9.3. (6.0.-9.0.,11.0.,12.0.)		G. İzbırak				
8.0.,9.0., 9.1.	IM	Y. Küçükardalı	2	1	1	**4**
4.0.,5.0.,8.0.	PP	M. Kaçar	4	2	2	**8**
14.0.	MG	A. Ç. Kuşkucu	5	2	2	**9**
9.2.	EM	S. Sarıkaya	1	0	0	**1**
8.0.,9.0., 9.1.	PED	S. Kemahlı H. Sarıçoban S. Yılmaz	5	2	2	**9**
	PHY	E. Yeşilada	3	0	0	**3**
TOTAL			90	22	22	**134**
LEARNING OBJECTIVE	**FACULTY DEPARTMENT**	**LECTURER/INSTRUCTOR**	**NUMBER OF QUESTIONS (EMQ)**			
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	M. Sönmezoğlu/ İ.Ç. Acuner/B.A.Borsa	2	-	-	**2**
10.0.	PC	E.Genç	1	-	-	**1**
	HEM	H.A.Özkan	1	-	-	**1**
4.0.,5.0.	PT	I. D. Ekici/F. Özkan	1	-	-	**1**
		TOTAL	**5**	-	-	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 pts; pts:points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

****22** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK I / 4-8 Sep 2017

	Monday 4-Sep-2017	Tuesday 5-Sep-2017	Wednesday 6-Sep-2017	Thursday 7-Sep-2017	Friday 8-Sep-2017
09.00- 09.50	**Religious Holiday**		**Introduction to Phase 3**	**Independent Learning**	**Lecture** Scientific Projects - III: Project Writing G. Y. Demirel
10.00- 10.50			**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Lecture** Introduction to Anemias in Childhood S. Kemahlı
11.00- 11.50			**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	GROUP A IL / GRPUP B IL / GROUP C IL / GROUP D IL	**Lecture** Antimicrobial Agents: Basic Concepts & Principles I İ.Ç.Acuner
12.00- 12.50			**Lecture** Laboratory Diagnosis of Infectious Diseases I İ.Ç. Acuner	GROUP A IL / GRPUP B / GROUP C IL / GROUP D IL	**Lecture** Antimicrobial Agents: Basic Concepts & Principles II İ.Ç.Acuner
12.50 - 14.00					
14.00- 14.50	**Religious Holiday**		**Lecture** Laboratory Diagnosis of Infectious Diseases II İ.Ç. Acuner	**Lecture** Introduction to Scientific Projects G. Yanıkkaya Demirel	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I B.A. Borsa
15.00- 15.50			**Lecture** Laboratory Diagnosis of Infectious Diseases III İ.Ç. Acuner	**Lecture** Introduction to Scientific Projects G. Yanıkkaya Demirel	**Lecture** Antimicrobial Agents: Mechanisms of Resistance I B.A. Borsa
16.00- 16.50			**Lecture** Laboratory Diagnosis of Infectious Diseases IV B.A. Borsa	**Lecture** Introduction to Antimicrobial Chemotherapy Pharmacology Lecturer	**Lecture** Introduction to Hemolytic Anemias Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) S. Kemahlı
17.00-17.50			**Lecture** Laboratory Diagnosis of Infectious Diseases V B.A. Borsa	**Independent Learning**	**Lecture** Hemophilia and other Coagulopathies in Childhood S. Kemahlı

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK II / 11-15 Sep 2017

	Monday 11-Sep-2017	Tuesday 12-Sep-2017	Wednesday 13-Sep-2017	Thursday 14-Sep-2017	Friday 15-Sep-2017
09.00- 09.50	**Case Discussions** Pathology Tissue Response to Infections F. Özkan	**Independent Learning**	**Lecture** Parasitic Infections I A.Ç. Büke	**Microbiology Laboratory** (Antibacterial Susceptibility Testing) Microbiology Instructors	**Independent Learning**
10.00- 10.50	**Case Discussions** General Rewiev of Pathology of Infections Disease F. Özkan	**Lecture** ß Lactam Antibiotics I Pharmacology Lecturer	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections M. Sönmezoğlu	GROUP A IL | GRPUP B | GROUP C | GROUP D IL	**Lecture** Vancomycin & Other Cell Wall Synthesis Inhibitors Pharmacology Lecturer
11.00- 11.50	**Lecture** Semiology-I A.Ç. Büke	**Lecture** ß Lactam Antibiotics II Pharmacology Lecturer	**Lecture** Aminoglycosides E.Genç	GROUP C IL | GROUP D	**Lecture** Macrolides Pharmacology Lecturer
12.00- 12.50	**Lecture** Semiology-II A.Ç. Büke	**Independent Learning**	**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E.Genç	**Independent Learning**	**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Independent Learning**	**Lecture** Introduction to the Course I Ethics Lecturer	**Lecture** Planning Medical Studies I Ç. Altunok	**Microbiology Laboratory** (Laboratory Tests-I) Microbiology Instructors
15.00- 15.50	**Lecture** Pathology of Mycobacterial Infections F. Özkan	**Independent Learning**	**Lecture** Introduction to the Course II Ethics Lecturer	**Lecture** Planning Medical Studies II Ç. Altunok	GROUP A | GROUP B IL | GROUP C IL | GROUP D IL
16.00- 16.50	**Lecture** Case discussion on immunity to infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Lecture** Research Design Ç. Altunok	GROUP A IL | GROUP B
17.00-17.50	**Lecture** Case discussion on immunity to infection G. Yanıkkaya Demirel	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK III / 18-22 Sep 2017

	Monday 18-Sep-2017	Tuesday 19-Sep-2016	Wednesday 20-Sep-2017	Thursday 21-Sep-2017	Friday 22-Sep-2017
09.00- 09.50	**Lecture** Tuberculosis & Other Mycobacterial Infections I A.Ç. Büke	**Lecture** Hospital Infection M. Sönmezoğlu	**Lecture** Public Health and Communicable Diseases-I R.E.Sezer	**Independent Learning**	**Lecture** Infections in Immuncompromised Host M. Sönmezoğlu
10.00- 10.50	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Lecture** Febril Neutropenia M. Sönmezoğlu	**Lecture** Public Health and Communicable Diseases-**II** R.E.Sezer	**Independent Learning**	**Lecture** Vaccines A.Ç. Büke
11.00- 11.50	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Lecture** Tuberculosis & Other Mycobacterial Infections II A.Ç. Büke	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu	**Independent Learning**	**Lecture** Prevention and Control of Communicable Diseases I R.E. Sezer
12.00- 12.50	**Lecture** Antimycobacterial Drugs E.Genç	**Lecture** Anthelminthic Drugs Pharmacology Lecturer	**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu	**Independent Learning**	**Lecture** Prevention and Control of Communicable Diseases II R.E. Sezer
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Confidentiality and Truthfulness I Ethics Lecturer	**Lecture** Occupational Health Hazards I A.Ç. Büke	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu	**Lecture** Antiviral Drugs Pharmacology Lecturer	**Independent Learning**
15.00- 15.50	**Lecture** Confidentiality and Truthfulness II Ethics Lecturer	**Lecture** Occupational Health Hazards II A.Ç. Büke	**Lecture** Parasitic Infections II A.Ç. Büke	**Lecture** Principles of Autonomy and Informed Consent I Ethics Lecturer	**Independent Learning**
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Principles of Autonomy and Informed Consent II Ethics Lecturer	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK IV / 25-29 Sep 2017

	Monday 25-Sep-2017	Tuesday 26-Sep-2017	Wednesday 27-Sep-2017	Thursday 28-Sep-2017	Friday 29-Sep-2017
09.00- 09.50	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar	**Independent Learning**	**Lecture** Antimalarial Drugs Pharmacology Lecturer	**Independent Learning**	**Lecture** Pharmacological Basis of Cancer Therapy I Pharmacology Lecturer
10.00- 10.50	**Lecture** Pathophysiology of Hematopoietic System Disorders II M. Kaçar	**ICP-CSL** (Suturing technique) M. F. Çelikmen	**Lecture** Quinolones Pharmacology Lecturer	**ICP-CSL** (Suturing technique) V. Öztürk	**Lecture** Pharmacological Basis of Cancer Therapy II Pharmacology Lecturer
11.00- 11.50	**Lecture** Antiprotozoal Drugs Pharmacology Lecturer	**Group A ICP** / **Group B Small Group Study** Scientific Project / **Group C IL** / **Group D IL**	**Lecture** Transplantation immunology G. Yanıkkaya Demirel	**Group A Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Pathology of Viral Infections I I.D.Ekici
12.00- 12.50	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen		**Lecture** Transplantation immunology G. Yanıkkaya Demirel		**Lecture** Pathology of Viral Infections II I.D.Ekici
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Physician-Patient Relationship I Ethics Lecturer	**Lecture** Antifungal Drugs Pharmacology Lecturer	**Lecture** Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias A . Özkan	**Lecture** Aplastic and Hypoplastic Anemias A.Özkan	**Lecture** Antianemic Drugs E. Genç
15.00- 15.50	**Lecture** Physician-Patient Relationship II Ethics Lecturer	**Lecture** Antiseptics and Disinfectants Pharmacology Lecturer	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu	**Lecture** Nutritional Anemias A.Özkan	**Independent Learning**
16.00- 16.50	**Lecture** Approach to the Pediatric Patient with Fever P. Saf	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK V / 2-6 Oct 2017

<table>
<tr><th></th><th>Monday
2-Oct-2017</th><th>Tuesday
3-Oct-2017</th><th>Wednesday
4-Oct-2017</th><th>Thursday
5-Oct-2017</th><th>Friday
6-Oct-2017</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Pathology of Bone Marrow-1
I D. Ekici</td><td>ICP-CSL
(Suturing technique)
M. Yazıcıoğlu / C. Şimşek</td><td>Lecture
Hodgkin’s Lymphoma
I D. Ekici</td><td colspan="4">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Pathology of Bone Marrow-2
I D. Ekici</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C Small Group Study
Scientific Project</td><td rowspan="2">Group D ICP</td><td>Lecture
Pathology of Myeloproliferative Diseases-I
I D. Ekici</td><td colspan="4">ICP
(Ear-Nose-Throat Examination)
R. Yılmazer/ S. Özdemir</td><td>Independent Learning</td></tr>
<tr><td>11.00- 11.50</td><td colspan="2">Microbiology Laboratory
(Laboratory Tests-I)
Microbiology Instructors</td><td rowspan="2">Lecture
Pathology of Myeloproliferative Diseases II
I D. Ekici</td><td rowspan="2">Group A ICP</td><td rowspan="2">Group B Small Group Study
Scientific Project</td><td rowspan="2">Group C IL</td><td rowspan="2">Group D IL</td><td rowspan="2">Lecture
Introduction to Radiation Oncology
H. Aydın</td></tr>
<tr><td>12.00- 12.50</td><td>Group A IL</td><td>Group B IL</td><td>Group C IL</td><td>Group D</td><td colspan="2">Independent Learning</td><td>Lecture
Antineoplastic Drugs I
Pharmacology Lecturer</td><td>Lecture
Basics of Radiation Biology and Radiation Physics
H. Aydın</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="8">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td colspan="3">ICP-CSL
(Suturing technique)
P. Türe</td><td rowspan="3" colspan="2">Microbiology Laboratory Make-up (Antibacterial & Susceptibility Testing)
Microbiology Instructors</td><td>Lecture
Epidemiology of Communicable Diseases I
H.A.Taşyıkan</td><td colspan="2">Lecture
Antineoplastic Drugs II
Pharmacology Lecturer</td><td>Independent Learning</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="2">Group A IL</td><td rowspan="2">Group B IL</td><td rowspan="2">Group C ICP</td><td rowspan="2">Group D Small Group Study
Scientific Project</td><td>Lecture
Epidemiology of Communicable Diseases II
H.A.Taşyıkan</td><td colspan="2">Lecture
Antineoplastic Drugs III
Pharmacology Lecturer</td><td>Independent Learning</td></tr>
<tr><td>16.00- 16.50</td><td>Independent Learning</td><td colspan="2">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>17.00-17.50</td><td colspan="2">Independent Learning</td><td colspan="2">Independent Learning</td><td>Independent Learning</td><td colspan="2">Independent Learning</td><td>Independent Learning</td></tr>
</table>

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VI / 9-13 Oct 2017

	Monday 9-Oct-2017	Tuesday 10-Oct-2017	Wednesday 11-Oct-2017	Thursday 12-Oct-2017	Friday 13-Oct-2017
09.00- 09.50	**Independent Learning**	**Independent Learning**	**Lecture** Scientific Projects- III: Project Writing G. Yanıkkaya Demirel	**Independent Learning**	**Lecture** Lymphoreactive Disease I D. Ekici
10.00- 10.50	**Lecture** Quantitative and Qualitative Platelet Disorders A.Özkan	**Lecture** Non/Hodgkin's Lymphoma I I D. Ekici	**Lecture** Introduction to Clinical Oncology I O .Ö.Eren	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Pathology of Spleen I D. Ekici
11.00- 11.50	**Lecture** Hypercoagulability A.Özkan	**Lecture** Non/Hodgkin's Lymphoma II I D. Ekici	**Lecture** Introduction to Clinical Oncology II O .Ö.Eren	**Group A IL** / **Group B IL** / **Group C ICP** / **Group D Small Group Study** Scientific Project	**Independent Learning**
12.00- 12.50	**Lecture** Plasma Cell Dyscrasias A.Özkan	**Lecture** Congenital Immunodeficiency Disease H. Sarıçoban	**Lecture** Treatment Approaches of Cancer O .Ö.Eren		**Independent Learning**
12.50 – 14.00					
14.00- 14.50	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A.Özkan	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Phytotherapy I E. Yeşilada	**Lecture** Lymphoma A.Özkan	**Independent Learning**
15.00- 15.50	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel	**Group A Small Group Study** Scientific Project / **Group B ICP** / **Group C IL** / **Group D IL**	**Lecture** Phytotherapy II E. Yeşilada	**Lecture** Acute Leukemias A.Özkan	**Independent Learning**
16.00- 16.50	**Lecture** Immunodeficiencies G. Yanıkkaya Demirel		**Lecture** Phytotherapy III E. Yeşilada	**Independent Learning**	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM
WEEK VII / 16-20 Oct 2017

	Monday 16-Oct-2017	Tuesday 17-Oct-2017	Wednesday 18-Oct-2017	Thursday 19-Oct-2017	Friday 20-Oct-2017
09.00- 09.50	**Lecture** Immunomodulators Pharmacology Lecturer	**Lecture** Lenforeticular Infections II A.Ç. Büke	**Lecture** Responsible Biomedical Research I Ethics Lecturer	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Lenforeticular Infections I A.Ç. Büke	**Lecture** Blood Components and Transfusion Indications M. Sönmezoğlu	**Lecture** Responsible Biomedical Research II Ethics Lecturer		**Independent Learning**
11.00- 11.50	**Lecture** Hematostatic Drugs and Hematostatic Blood Products I E. Genç	**Lecture** Blood Groups M. Sönmezoğlu	**Lecture** Myeloproliferative Diseases A.Özkan		**Independent Learning**
12.00- 12.50	**Lecture** Hematostatic Drugs and Hematostatic Blood Products II E. Genç	**Lecture** Approach to the Patient with LAP H. Akan	**Lecture** Chronic Leukemia A.Özkan		**Independent Learning**
12.50-14.00	**Lunch break**				
14.00- 14.50	**Independent Learning**	**Lecture** Genetics of Oncology I A.Ç. Kuşkucu	**Lecture** Investigation of a Disease Epidemic I H.A.Taşyıkan	**Independent Learning**	**Independent Learning**
15.00- 15.50	**ICP** (Ear-Nose-Throat Examination) R. Yılmazer/ S. Özdemir	**Lecture** Genetics of Oncology II A.Ç. Kuşkucu	**Lecture** Investigation of a Disease Epidemic II H.A.Taşyıkan	**Independent Learning**	**Independent Learning**
16.00- 16.50	**Group A IL** / **Group B IL** / **Group C Small Group Study** Scientific Project / **Group D ICP**	**Independent Learning**	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	**Independent Learning**
17.00-17.50		**Independent Learning**	**Multidisciplinary Case Discussion Panel**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES and HEMATOPOIETIC SYSTEM

WEEK VIII / 23-27 Oct 2017

<table>
<tr><th></th><th>Monday
23-Oct-2017</th><th>Tuesday
24-Oct-2017</th><th>Wednesday
25-Oct-2017</th><th>Thursday
26-Oct-2017</th><th>Friday
27-Oct-2017</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Program Evaluation Session
Committee I Coordination Committee Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>